SPLITOAK STRATEGIES LLC for ALKERMES, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Maintain access to mental health medications for the low-income subsidy (LIS) eligible population under Medicare Part D in prescription drug reform legislation -- H.R.5376 - Inflation Reduction Act implementation issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Health Issues HCR
Awareness of the need for access to all FDA-approved medications for treatment of substance use disorder Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder Initiatives to promote the use of relapse prevention post detoxification Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings in FY23 appropriations for Labor-HHS and CJS bills -- H.R. 2617, Consolidated Appropriations Act, 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.